The FDA granted accelerated approval to Blenrep (belantamab mafodotin-blmf), developed by GlaxoSmithKline plc (GSK), on August 5, 2020, for the treatment of adult patients with relapsed or refractory multiple myeloma.Blenrep is the first anti-BCMA (B-cell maturation antigen) therapy approved for the treatment of multiple myeloma patients who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.The list price for the drug is set as $8,277 per vial, which comes out to about $23,900 per month.Analysts at SVB Leerink expect the drug to bring in sales of $377 million in 2021 and $1.93 billion in 2024.Blenrep comes with a boxed warning about ocular toxicity and is available through participation in the Risk Evaluation and Mitigation Strategy (REMS).